Brooks Announces GENEWIZ Selected as Genome Characterization Center by the National Cancer Institute

CHELMSFORD, Mass., Jan. 12, 2021 /PRNewswire/ --Brooks Automation, Inc. (Nasdaq:BRKS) announced today that GENEWIZ, the Company's genomics analysis business, has been awarded one of six Genome Characterization Center Indefinite Delivery Indefinite Quantity (IDIQ) contracts from the National Cancer Institute (NCI).